| Budget Amount *help |
¥16,380,000 (Direct Cost: ¥12,600,000、Indirect Cost: ¥3,780,000)
Fiscal Year 2016: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2015: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2014: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|
|---|
| Outline of Final Research Achievements |
An adenovirus (Ad) genome encodes two non-coding RNAs, VA-RNA I and VA-RNA II. Previous studies demonstrated that VA-RNAs enhance Ad infection and that Dicer processes VA-RNAs, producing miRNA-like small RNAs (mivaRNA); however, relationship between Dicer-mediated processing of VA-RNAs and VA-RNA-mediated enhancement of Ad infection remained to be elucidated. In this study, we examined the effects of Dicer-mediated processing of VA-RNAs on Ad infection. We demonstrated that Dicer-mediated proessing of VA-RNA I resulted in loss of promotion activity of VA-RNA I for Ad infection. Based on these findings, we developed a novel oncolytic Ad showing superior antitumor effects.
|
